(ISRG) Intuitive Surgical, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ISRG) Intuitive Surgical, Inc. Bundle
Visual. Strategic. Downloadable.
This Intuitive Surgical, Inc. BCG Matrix helps you see how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework. It is used for strategy, portfolio review, and capital allocation, and this page already shows a real preview of the analysis so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
da Vinci 5 system
da Vinci 5 is Intuitive Surgical, Inc.'s newest flagship system and the clearest Star in the BCG Matrix. With more than 10,500 da Vinci systems installed worldwide and 2024 revenue of $8.4 billion, Intuitive is using this platform to push growth in a large, still-expanding minimally invasive surgery market. Early placements and premium pricing should drive more procedures and future ecosystem sales.
da Vinci Xi platform
da Vinci Xi is Intuitive Surgical, Inc.'s core multiport robotic platform, with 9,500+ systems installed worldwide and continued procedure growth in 2025. It still anchors many hospitals' robotic soft-tissue surgery programs, so it keeps Intuitive Surgical, Inc. in the lead. That makes it a "Star": high share in a growing market.
da Vinci SP platform
da Vinci SP is Intuitive Surgical, Inc.'s single-port robot for narrow-access cases, so it fits the Stars box: high growth, rising adoption, and strategic upside. The platform is already used in urology, colorectal, and ENT, and Intuitive Surgical reported 2024 revenue of $8.35 billion, showing the scale behind the broader ecosystem. Its growth depends on new clinical wins and label expansion, but in a still-growing market, that gives it strong BCG momentum.
Robotic-assisted soft-tissue surgery leadership
Intuitive Surgical stays the clear leader in robotic-assisted soft-tissue surgery, with a global installed base above 10,000 da Vinci systems and annual procedures above 2.7 million. That scale gives the brand strong pull-through for instruments, accessories, and service.
Hospitals still keep adding robotic programs, so the market is expanding rather than fading. High case volume reinforces surgeon preference and makes Intuitive Surgical harder to displace, which fits Star status in the BCG Matrix.
- Leader in robotic-assisted surgery
- Large and growing procedure volume
- Strong brand and system pull-through
- Supports Star classification
International system placements
In 2025, Intuitive Surgical kept expanding its international installed base as robotic surgery adoption rose outside the U.S. These markets still start from a smaller base, so each new system can drive follow-on sales of instruments, accessories, and service. That growth-plus-reinvestment pattern fits a Star in the BCG Matrix.
- 2025: global expansion stayed a key driver.
- Outside-U.S. placements kept rising.
- Smaller base, higher growth, continued support.
Intuitive Surgical’s Star Growth Is Still Running Strong
Intuitive Surgical, Inc.'s Stars are led by da Vinci 5, Xi, and SP. With 10,500+ systems installed and 2.7 million+ annual procedures, the platform still sits in a large, growing market. 2024 revenue was $8.4 billion, and 2025 international growth kept the Stars profile intact.
| Metric | Data |
|---|---|
| Installed base | 10,500+ |
| Annual procedures | 2.7M+ |
| 2024 revenue | $8.4B |
What is included in the product
Detailed Word Document
Intuitive Surgical BCG Matrix: map da Vinci systems and services into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest.
Editable Excel File
One-page Intuitive Surgical BCG Matrix to quickly spot growth, cash, and drag across the portfolio
Reference Sources
Intuitive Surgical, Inc. reference sources provide a credible audit trail that supports faster, more confident decisions.
Cash Cows
Instruments and accessories
Instruments and accessories are Intuitive Surgical, Inc.'s core cash cow because every installed da Vinci system drives repeat sales of procedure-linked consumables across thousands of surgeries. Revenue is steadier than system placements, but the volume is much larger and the recurring mix helps support strong cash generation.
Service and maintenance contracts
Intuitive Surgical, Inc. had about 8,600 da Vinci systems installed worldwide, and each one drives recurring service and maintenance work. These contracts are tied to the base, so cash flow is steady and far less cyclical than new system sales. Service revenue also carries high margins, which makes this a classic Cash Cow.
Training and clinical support
Intuitive Surgical’s training and clinical support is a cash cow because it helps hospitals adopt da Vinci and keeps procedures flowing after install. In FY2024, revenue reached $8.35 billion and da Vinci procedures rose 17%, showing how support turns the installed base into repeat use. Once teams are trained, service costs stay relatively contained while retention and utilization stay high.
Stapling and energy device consumables
Stapling and energy device consumables are a Cash Cow because they are used again and again across procedures, so demand tracks Intuitive Surgical, Inc.'s installed da Vinci base rather than new market creation. In 2024, the Company reported 2.68 million procedures and $8.35 billion in revenue, which shows how recurring tool use turns a mature footprint into steady cash flow.
- Repeat use in each surgery
- Sales follow installed systems
Installed base upgrades and refurbishments
Intuitive Surgical, Inc.'s installed base is a cash cow because hospitals often refresh instruments, parts, and software instead of swapping out full da Vinci systems. With a global installed base above 9,000 systems and 2024 revenue of $8.35 billion, the Company keeps turning its fleet into recurring service and upgrade cash.
- Lower cost than new system sales
- Recurring revenue from upgrades
- Large installed base cuts sales risk
- Stable monetization with service tie-ins
This makes refurbishments and component upgrades a steady, high-margin engine, while the scale of the base reduces reliance on new hospital wins.
Intuitive Surgical’s Recurring Cash Machine
Intuitive Surgical, Inc.'s Cash Cows are the repeat-sale lines tied to its large installed da Vinci base: instruments, accessories, service, and support. In FY2025, the Company kept turning recurring procedure use into steady cash, with a base near 9,000 systems and high-margin follow-on sales.
| Cash cow | FY2025 signal |
|---|---|
| Consumables | Repeat use per surgery |
| Service | Installed-base linked |
| Support | Drives retention |
What You See Is What You Get
Intuitive Surgical, Inc. Reference Sources
You're previewing the exact Intuitive Surgical, Inc. BCG Matrix report you'll receive after purchase. This is the same fully formatted document—no placeholders, no demo content, and no watermarks. Once purchased, the full file is delivered instantly for download and use. What you see here is what you get.
Dogs
Legacy da Vinci S systems
Legacy da Vinci S systems are mature, low-growth assets with weak share versus newer Intuitive Surgical platforms. They are mostly kept in service for maintenance and selective replacements, not new demand, and hospitals are shifting to higher-capability systems. In BCG terms, they fit the "dog" profile: low growth, low strategic pull, and limited upgrade economics.
Legacy da Vinci Si systems
Legacy da Vinci Si systems are older multiport units still in the field, but they have far less strategic weight than Xi and da Vinci 5. New placements are now limited, so the value pool is mostly service, parts, and upkeep of the existing installed base. That is classic Dog territory: low growth, low upgrade pull, and fading relevance.
Obsolete training simulators
Obsolete training simulators fit a Dogs role because they serve legacy users more than new demand. Intuitive Surgical reported 2.68 million da Vinci procedures in 2024 and a 10% rise, but hospitals are shifting to integrated digital training tied to newer systems, not stand-alone legacy tools. That leaves older simulators with limited growth and weak expansion value.
Low-volume legacy accessory SKUs
Low-volume legacy accessory SKUs are classic Dogs for Intuitive Surgical, Inc.: they mainly exist to support a 2025 installed base of 9,000+ da Vinci systems, not to grow fast. Small, older parts can trap cash in inventory and service time, while revenue stays limited versus 2025 company revenue of about $9 billion. They’re weak portfolio items unless they protect uptime.
- Low demand
- Inventory drag
- Support-heavy
- Installed-base only
Non-core legacy service-only accounts
These non-core legacy service-only accounts fit closer to Dogs than Stars: they mostly keep older systems running, so incremental growth stays low and the economics are thinner than new da Vinci placements or recurring instrument sales. In Intuitive Surgical, Inc.’s FY2025 mix, growth still came mainly from higher procedure volume, newer system placements, and recurring instruments, not from these aging accounts.
- Old base, low growth
- Service-heavy, narrow margins
- Weak upsell potential
- Dog, not Star
Intuitive’s Legacy “Dogs” Still Linger, But Growth Comes From Elsewhere
Dogs in Intuitive Surgical, Inc. are the legacy da Vinci S and Si systems, obsolete simulators, and low-volume accessory SKUs. They have little new demand, weak upgrade pull, and mostly generate service or parts revenue from the installed base. FY2025 revenue was about $9.0 billion, but these items added little growth versus 2.68 million procedures.
| Dog item | FY2025 signal |
|---|---|
| da Vinci S/Si | Legacy, low-growth |
| Training simulators | Obsolete, limited demand |
| Accessory SKUs | Installed-base only |
Question Marks
Ion endoluminal system
Ion endoluminal system targets minimally invasive lung biopsy, a large and still underused market: lung cancer remains the top cancer killer, and U.S. screening uptake is only about 16% of eligible patients. Strategically, it matters, but its base is far smaller than da Vinci, so Intuitive Surgical is still pushing adoption and procedure volume. That is a textbook Question Mark.
da Vinci 5 early-market adoption
da Vinci 5 is still in early adoption, so installed base is small versus Intuitive Surgical, Inc.'s older da Vinci fleet. In 2024, Intuitive Surgical, Inc. reported $8.35 billion in revenue and continued to expand procedure volume, but da Vinci 5 still has to win hospital budgets and surgeon preference. That makes it a high-potential Question Mark that needs steady capital and sales support.
Single-port expansion into new specialties
Single-port still fits Question Mark status: Intuitive Surgical, Inc. says it is expanding SP into more specialties, but the SP base is still far smaller than the multiport franchise. In 2024, Intuitive Surgical completed 2.7 million procedures worldwide, and SP remained a small share of that volume. Adoption still hinges on surgeon training and stronger procedure-specific evidence.
Intuitive digital and analytics tools
Intuitive digital and analytics tools are a Question Mark: connected surgery software can improve hospital throughput and case visibility, but the category is still early and crowded. Intuitive Surgical’s big installed base helps, with 2.68 million da Vinci procedures and 9,500+ systems worldwide, yet monetization still depends on turning hardware customers into software buyers.
- Large base, weak software lock-in.
- Growth is real, competition is intense.
- Value depends on conversion rates.
- Still an emerging Question Mark.
New procedure indication expansion
New specialties are a Question Mark for Intuitive Surgical: FY2024 da Vinci procedure volume rose 17% to 2.68 million, but each new use case still starts small and must prove clinical value, secure reimbursement, and win hospital adoption. With FY2024 revenue of $8.36 billion and 15,000+ installed systems, the market is expanding, but uptake is uneven.
- High upside, low current share
- Needs proof, reimbursement, adoption
- Growth bet, not a cash cow yet
Intuitive Surgical’s Growth Bets Still Need Proof
Intuitive Surgical, Inc. Question Marks are still early bets: Ion, da Vinci 5, single-port, and software all have upside, but each has a small installed base and still needs proof, reimbursement, and surgeon adoption. In FY2024, revenue was $8.36B and da Vinci procedure volume reached 2.68M, but new platforms remain far from core cash generation.
| Item | FY2024 | Status |
|---|---|---|
| Revenue | $8.36B | Strong base |
| Procedures | 2.68M | Core growth |
| Systems | 15,000+ | Large fleet |
| New platforms | Early | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.